Pharma Focus Europe


The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

TFF Pharmaceuticals Inc. And Uniphar Durbin Ireland Ltd. Announce the Launch of Expanded Access Program for Voriconazole Inhalation Powder

Monday, July 31, 2023

Uniphar Durbin Ireland Limited Durbin or the Company and TFF Pharmaceuticals Inc Nasdaq TFFP have jointly announced the launch of an Expanded Access Program EAP for TFFVORI

Ionis Completes Enrollment in Pivotal Phase 3 CARDIO-TTRansform Trial for Patients With TTR-mediated Amyloid Cardiomyopathy

Monday, July 31, 2023

Ionis Pharmaceuticals Inc Nasdaq IONS has successfully completed the enrollment phase of the Phase CARDIOTTRansform cardiovascular outcomes study for eplontersen an investigational drug targeting transthyretinmediated amyloid cardiomyopathy ATTRCM

Marinus Pharmaceuticals Receives European Commission Approval for ZTALMY® (Ganaxolone) as Adjunctive Therapy for Epileptic Seizures Associated With CDKL5 Deficiency Disorder

Monday, July 31, 2023

Marinus Pharmaceuticals Inc Nasdaq MRNS has received approval from the European Commission EC for the oral suspension medication ZTALMY ganaxolone

IO Biotech Commences Phase 1 Trial, Administers First Dose to Patient at University of California Davis Comprehensive Cancer Center

Saturday, July 29, 2023

IO Biotech Nasdaq IOBT has recently announced the initiation of an investigatorinitiated trial in collaboration with the University of California Davis Comprehensive Cancer Center

FDA Grants Breakthrough Therapy Designation to NS-089/NCNP-02 for Duchenne Muscular Dystrophy Treatment

Saturday, July 29, 2023

NS Pharma Inc announced today that the US Food Drug Administration FDA has granted Breakthrough Therapy Designation to NSNCNP an investigational candidate developed for patients with Duchenne muscular dystrophy amenable to exon skipping therapy

Genenta's Ongoing Clinical Trial Progress and Ambitious Plans for Solid Tumor Treatments

Saturday, July 29, 2023

Genenta Science NASDAQ GNTA has provided an update on its clinicalstage immunooncology IO efforts focusing on the development of Temferon a cellbased platform aimed at providing safe and durable treatments for solid tumors

Peptomyc Receives Approval for Phase 1b Trial Testing OMO-103 in Combination with Standard of Care for PDAC Patients

Friday, July 28, 2023

Peptomyc SL is a specialized biotech company dedicated to developing protein therapeutics for cancer treatment The company has received full approval for its Phase b clinical trial which aims to evaluate the combination of OMO a groundbreaking MYC in...

Celularity and Verséa Ophthalmics Establish Exclusive Agreement to Commercialize Biovance® and Biovance® 3L Ocular for Ophthalmic Applications in the U.S.

Friday, July 28, 2023

Celularity Inc Nasdaq CELU and Versa Ophthalmics LLC have entered into an exclusive US commercialization agreement according to their joint announcement Versa Ophthalmics a company based in Tampa FL specializes in delivering complete ocular pointofca...

Recce Pharmaceuticals Initiates Phase I/II Rapid Infusion Clinical Trial of RECCE® 327 for UTI at Scientia Clinical Research

Thursday, July 27, 2023

Reece Pharmaceuticals Ltd ASX RCE FSE RQ has made an exciting announcement regarding the progress of its Phase III clinical trial for a new class of synthetic antiinfectives targeting urinary tract infections UTIs

Myopax's Novel Regenerative Cell Therapy for Exstrophy-Epispadias Complex Granted FDA Orphan Drug Designation

Thursday, July 27, 2023

MyoPax a biotechnology company has received Orphan Drug Designation from the US Food and Drug Administration FDA for its advanced regenerative cell therapy aimed at treating ExstrophyEpispadias Complex EEC

Get instant
access to our latest e-book